Vapogenix, Inc., a Houston, TX-based clinical stage pharmaceutical company that is developing a new class of non-narcotic, locally-acting analgesics, completed a $5.1M Series B financing.
The round was led by Pamoja Capital and GPG Ventures.
Led by Danguole Altman, President and CEO, and Allen Burton, MD, co-Founder and Chairman of its Scientific Advisory Board, Vapogenix is advancing two programs: an acting topical analgesic to alleviate pain associated with venous access and minor dermatological procedures and a treatment of pain associated with chronic wounds. The company’s technology is based on the finding that volatile anesthetics, which are only used by inhalation for general anesthesia, can reduce pain locally.
The company, which has formulated these volatile anesthetics into topical gels and liquids to treat a variety of painful conditions, intends to use the funds to advance the aforementioned programs.